A Hitchhiker's Guide Through the COVID-19 Galaxy

Overview

Journal Clin Immunol

Specialty Allergy & Immunology

Date 2021 Sep 26

PMID 34563684

Citations 3

Authors

Susanna Felsenstein

Andreas Otto Reiff

Affiliations

Soon will be listed here.

Abstract

Numerous reviews have summarized the epidemiology, pathophysiology and the various therapeutic aspects of Coronavirus disease 2019 (COVID-19), but a practical guide on "how to treat whom with what and when" based on an understanding of the immunological background of the disease stages remains missing. This review attempts to combine the current knowledge about the immunopathology of COVID-19 with published evidence of available and emerging treatment options. We recognize that the information about COVID-19 and its treatment is rapidly changing, but hope that this guide offers those on the frontline of this pandemic an understanding of the host response in COVID-19 patients and supports their ongoing efforts to select the best treatments tailored to their patient's clinical status.

Citing Articles

Regadenoson for the treatment of COVID-19: A five case clinical series and mouse studies.

Rabin J, Zhao Y, Mostafa E, Al-Suqi M, Fleischmann E, Conaway M PLoS One. 2023; 18(8):e0288920.

PMID: 37566593 PMC: 10420352. DOI: 10.1371/journal.pone.0288920.

Tetrandrine Treatment May Improve Clinical Outcome in Patients with COVID-19.

Chen S, Liu Y, Ge J, Yin J, Shi T, Ntambara J Medicina (Kaunas). 2022; 58(9).

PMID: 36143871 PMC: 9503147. DOI: 10.3390/medicina58091194.

Key Considerations for Phase 2 or 3 Clinical Study Design of Anti-Inflammatory Agent for COVID-19 Treatment.

Park Y, Na J, Cho J, Oh J, Rhee S Front Pharmacol. 2022; 13:842836.

PMID: 35721224 PMC: 9201470. DOI: 10.3389/fphar.2022.842836.

References

Philippe A, Chocron R, Gendron N, Bory O, Beauvais A, Peron N . Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality. Angiogenesis. 2021; 24(3):505-517. PMC: 7809553. DOI: 10.1007/s10456-020-09762-6. View

Wu Z, McGoogan J . Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13):1239-1242. DOI: 10.1001/jama.2020.2648. View

Whitcomb D, Muddana V, Langmead C, Houghton Jr F, Guenther A, Eagon P . Angiopoietin-2, a regulator of vascular permeability in inflammation, is associated with persistent organ failure in patients with acute pancreatitis from the United States and Germany. Am J Gastroenterol. 2010; 105(10):2287-92. DOI: 10.1038/ajg.2010.183. View

Verma A, Adhikary A, Woloschak G, Dwarakanath B, Papineni R . A combinatorial approach of a polypharmacological adjuvant 2-deoxy-D-glucose with low dose radiation therapy to quell the cytokine storm in COVID-19 management. Int J Radiat Biol. 2020; 96(11):1323-1328. DOI: 10.1080/09553002.2020.1818865. View

Elsawah H, Elsokary M, Elrazzaz M, Elshafie A . Hydroxychloroquine for treatment of nonsevere COVID-19 patients: Systematic review and meta-analysis of controlled clinical trials. J Med Virol. 2020; 93(3):1265-1275. PMC: 7461373. DOI: 10.1002/jmv.26442. View

Caricchio R, Gallucci M, Dass C, Zhang X, Gallucci S, Fleece D . Preliminary predictive criteria for COVID-19 cytokine storm. Ann Rheum Dis. 2020; 80(1):88-95. DOI: 10.1136/annrheumdis-2020-218323. View

Jagannathan P, Andrews J, Bonilla H, Hedlin H, Jacobson K, Balasubramanian V . Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial. Nat Commun. 2021; 12(1):1967. PMC: 8009873. DOI: 10.1038/s41467-021-22177-1. View

Horby P, Lim W, Emberson J, Mafham M, Bell J, Linsell L . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 384(8):693-704. PMC: 7383595. DOI: 10.1056/NEJMoa2021436. View

Petito E, Falcinelli E, Paliani U, Cesari E, Vaudo G, Sebastiano M . Association of Neutrophil Activation, More Than Platelet Activation, With Thrombotic Complications in Coronavirus Disease 2019. J Infect Dis. 2020; 223(6):933-944. PMC: 7798977. DOI: 10.1093/infdis/jiaa756. View

10.

Pan H, Peto R, Henao-Restrepo A, Preziosi M, Sathiyamoorthy V, Abdool Karim Q . Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med. 2020; 384(6):497-511. PMC: 7727327. DOI: 10.1056/NEJMoa2023184. View

11.

Pereda R, Gonzalez D, Rivero H, Rivero J, Perez A, Lopez L . Therapeutic Effectiveness of Interferon-α2b Against COVID-19: The Cuban Experience. J Interferon Cytokine Res. 2020; 40(9):438-442. DOI: 10.1089/jir.2020.0124. View

12.

Channappanavar R, Fehr A, Zheng J, Wohlford-Lenane C, Abrahante J, Mack M . IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. J Clin Invest. 2019; 129(9):3625-3639. PMC: 6715373. DOI: 10.1172/JCI126363. View

13.

Gajic O, Dabbagh O, Park P, Adesanya A, Chang S, Hou P . Early identification of patients at risk of acute lung injury: evaluation of lung injury prediction score in a multicenter cohort study. Am J Respir Crit Care Med. 2010; 183(4):462-70. PMC: 3056224. DOI: 10.1164/rccm.201004-0549OC. View

14.

Wiersinga W, Rhodes A, Cheng A, Peacock S, Prescott H . Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020; 324(8):782-793. DOI: 10.1001/jama.2020.12839. View

15.

Spinner C, Gottlieb R, Criner G, Lopez J, Cattelan A, Soriano Viladomiu A . Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2020; 324(11):1048-1057. PMC: 7442954. DOI: 10.1001/jama.2020.16349. View

16.

Hagman K, Hedenstierna M, Gille-Johnson P, Hammas B, Grabbe M, Dillner J . Severe Acute Respiratory Syndrome Coronavirus 2 RNA in Serum as Predictor of Severe Outcome in Coronavirus Disease 2019: A Retrospective Cohort Study. Clin Infect Dis. 2020; 73(9):e2995-e3001. PMC: 7499508. DOI: 10.1093/cid/ciaa1285. View

17.

Rendeiro A, Casano J, Vorkas C, Singh H, Morales A, DeSimone R . Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression. Life Sci Alliance. 2020; 4(2). PMC: 7768198. DOI: 10.26508/lsa.202000955. View

18.

Homma Y, Katsuta T, Oka H, Inoue K, Toyoshima C, Iwaki H . The incubation period of the SARS-CoV-2 B1.1.7 variant is shorter than that of other strains. J Infect. 2021; 83(2):e15-e17. PMC: 8225994. DOI: 10.1016/j.jinf.2021.06.011. View

19.

Vogt K, Summers C, Chilvers E, Condliffe A . Priming and de-priming of neutrophil responses in vitro and in vivo. Eur J Clin Invest. 2018; 48 Suppl 2:e12967. DOI: 10.1111/eci.12967. View

20.

Cron R, Caricchio R, Chatham W . Calming the cytokine storm in COVID-19. Nat Med. 2021; 27(10):1674-1675. DOI: 10.1038/s41591-021-01500-9. View